Search results
EyePoint Pharmaceuticals’ stock plunges as eye treatment fails to meet trial goal
Market Watch· 20 hours agodropped nearly 30% in premarket trading Monday after the company said its experimental...
Can At-Home Vision Tests Detect Active Neovascular AMD?
MedPage Today· 5 days agoThree at-home vision-monitoring tools failed to detect worsening neovascular age-related macular ...
...Awarded $4 Million CIRM Grant to Support Clinical Trial of Adult RPESC-RPE-4W Therapy for Dry Age...
Benzinga· 6 days agoLuxa Biotechnology (LuxaBio), a joint venture between Y2 Solution Co. Ltd, Seoul, South Korea and the Neural Stem Cell Institute (NSCI) in Rensselaer, New York, today announced receipt of a $4 million grant from the
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 8 hours agoOcular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative ...
Stealth BioTherapeutics Announces Participation at Upcoming Ophthalmology Conferences
WKBN 27 Youngstown· 6 days agoAt the OIS Retina Innovation...
Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?
Benzinga via Yahoo Finance· 18 hours agoOn Monday, EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) announced the topline results of its Phase 2...
Scientists find potential treatment target for leading cause of blindness
Investing.com· 5 days agoNew Delhi, May 2 (IANS) US scientists have found answers to why treatment for neovascular age-...
Research to Prevent Blindness Opens Applications for Vision Research Grants
Newswise· 2 days agoWith a focus on scientific excellence, RPB funds research across all sight-threatening conditions, including glaucoma, age-related macular</ ...
A Revolution In Gene Therapy Is Unfolding, Bringing Hope for Vision Loss
Newswise· 4 days agoTwo treatments for retinal diseases, invented by Neena Haider, PhD, that currently are in clinical trials run by Ocugen, represent a conceptually broad, new approach that ...
EyePoint tumbles 30% premarket on failed Phase 2 study (NASDAQ:EYPT)
Seeking Alpha· 19 hours agoEyePoint (EYPT) stock tumbled nearly 30% in premarket trading Monday after the company said a Phase...
